Coloplast Dirección

Dirección controles de criterios 4/4

El CEO de Coloplast's es Kristian Villumsen , nombrado en Dec 2018, tiene una permanencia de 5.33 años. compensación anual total es DKK23.30M, compuesta por 51.5% salario y 48.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.045% de las acciones de la empresa, por valor de DKK93.38M. La antigüedad media del equipo directivo y de la junta directiva es de 6 años y 6.3 años, respectivamente.

Información clave

Kristian Villumsen

Chief Executive Officer (CEO)

kr.23.3m

Compensación total

Porcentaje del salario del CEO	51.5%
Permanencia del CEO	5.4yrs
Participación del CEO	0.05%
Permanencia media de la dirección	6.1yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Recent updates

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Apr 13

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Mar 29

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 12

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Jan 12

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Dec 28

Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All

Nov 25

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Oct 31

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Oct 02

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

Sep 16

Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?

Aug 02

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Jul 01

Does Coloplast (CPH:COLO B) Deserve A Spot On Your Watchlist?

Jun 16

Coloplast A/S (CPH:COLO B) Shares Could Be 34% Above Their Intrinsic Value Estimate

May 02

Would Coloplast A/S (CPH:COLO B) Be Valuable To Income Investors?

Apr 11

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Mar 29

Will Weakness in Coloplast A/S' (CPH:COLO B) Stock Prove Temporary Given Strong Fundamentals?

Mar 16

I Built A List Of Growing Companies And Coloplast (CPH:COLO B) Made The Cut

Mar 02

Did You Participate In Any Of Coloplast's (CPH:COLO B) Fantastic 123% Return ?

Feb 17

What Percentage Of Coloplast A/S (CPH:COLO B) Shares Do Insiders Own?

Feb 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kristian Villumsen en comparación con los beneficios de Coloplast?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	kr.5b
Sep 30 2023	kr.23m	kr.12m	kr.5b
Jun 30 2023	n/a	n/a	kr.5b
Mar 31 2023	n/a	n/a	kr.5b
Dec 31 2022	n/a	n/a	kr.5b
Sep 30 2022	kr.21m	kr.12m	kr.5b
Jun 30 2022	n/a	n/a	kr.5b
Mar 31 2022	n/a	n/a	kr.5b
Dec 31 2021	n/a	n/a	kr.5b
Sep 30 2021	kr.22m	kr.11m	kr.5b
Jun 30 2021	n/a	n/a	kr.5b
Mar 31 2021	n/a	n/a	kr.4b
Dec 31 2020	n/a	n/a	kr.4b
Sep 30 2020	kr.20m	kr.11m	kr.4b
Jun 30 2020	n/a	n/a	kr.4b
Mar 31 2020	n/a	n/a	kr.4b
Dec 31 2019	n/a	n/a	kr.4b
Sep 30 2019	kr.17m	kr.10m	kr.4b
Jun 30 2019	n/a	n/a	kr.4b
Mar 31 2019	n/a	n/a	kr.4b
Dec 31 2018	n/a	n/a	kr.4b
Sep 30 2018	kr.11m	kr.6m	kr.4b
Jun 30 2018	n/a	n/a	kr.4b
Mar 31 2018	n/a	n/a	kr.4b
Dec 31 2017	n/a	n/a	kr.4b
Sep 30 2017	kr.10m	kr.6m	kr.4b

Compensación vs. Mercado: La compensación total ($USD3.35M) de Kristian está en línea con el promedio de empresas de tamaño similar en el mercado Danish ($USD4.18M).

Compensación vs. Ingresos: La compensación de Kristian ha sido consistente con los resultados de la empresa en el último año.

CEO

Kristian Villumsen (53 yo)

5.4yrs

Permanencia

kr.23,300,000

Compensación

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kristian Villumsen	President & CEO	5.4yrs	kr.23.30m	0.045% DKK 85.2m
Anders Lonning-Skovgaard	Executive VP & CFO	9.8yrs	kr.11.90m	0.0012% DKK 2.2m
Allan Rasmussen	Executive Vice President of Global Operations	9.8yrs	kr.10.50m	0% DKK 0
Nicolai Andersen	Executive Vice President of Innovation	no data	kr.10.00m	sin datos
Paul Marcun	Executive Vice President of Growth	5.3yrs	kr.12.00m	sin datos
Thomas Barfod	Senior Controller & Employees Representative Director	no data	kr.450.00k	0.000020% DKK 37.8k
Ellen Bjurgert	Vice President of Investor Relations	7.6yrs	sin datos	sin datos
Dennis Kaysen	Director of Corporate Communications	no data	sin datos	sin datos
Dorthe Ronnau	Senior Vice President of People & Culture	2.3yrs	sin datos	sin datos
Alain Morvan	Senior Vice President of Sales Europe	12.1yrs	sin datos	sin datos
Rasmus Møller	Senior Vice President of Wound & Skin Care	3.7yrs	sin datos	sin datos
Manu Varma	Senior Vice President of Chronic Care - North America	6.1yrs	sin datos	sin datos

6.1yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de COLO B es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Barfod	Senior Controller & Employees Representative Director	18.3yrs	kr.450.00k	0.000020% DKK 37.8k
Carsten Hellmann	Independent Director	6.4yrs	kr.690.00k	0.0027% DKK 5.0m
Lars Rasmussen	Chairman of the Board	5.4yrs	kr.1.84m	0.092% DKK 174.5m
Niels Louis-Hansen	Deputy Chairman	56.3yrs	kr.938.00k	1.93% DKK 3.6b
Marianne Wiinholt	Independent Director	3.4yrs	kr.880.00k	0.00022% DKK 416.0k
Jette Nygaard-Andersen	Independent Director	8.4yrs	kr.600.00k	sin datos
Nikolaj Gundersen	Employees Representative Director	6.3yrs	kr.450.00k	sin datos
Roland Pedersen	Employees Representative Director	6.3yrs	kr.450.00k	0.00072% DKK 1.4m
Annette Bruls	Independent Director	2.4yrs	kr.600.00k	sin datos

6.3yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de COLO B se considera experimentada (6.3 años de antigüedad promedio).

Coloplast Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

President & CEO exercised options and sold kr.13m worth of stock

Deputy Chairman recently bought kr.40m worth of stock

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Recent updates

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Third quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Contraline Names Yelena Tropsha as CTO

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?